Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.76 USD | -2.22% | +14.62% | +87.54% |
05:24pm | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
05-10 | Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+87.54% | 488M | |
+47.96% | 54.63B | |
-6.31% | 39.92B | |
+37.07% | 38.82B | |
+13.79% | 26.86B | |
-11.17% | 26.22B | |
-20.98% | 18.78B | |
+25.49% | 12.21B | |
+1.00% | 12.16B | |
+26.03% | 11.94B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Transcript : Neoleukin Therapeutics, Inc. - Shareholder/Analyst Call